Related Experiment Videos
Tardive dyskinesia in affective disorders
1Department of Psychiatry, Hillside Hospital, Division of North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA.
The Journal of Clinical Psychiatry
|April 7, 1999
Summary
Patients with affective disorders face higher risks of tardive dyskinesia from antipsychotic drugs. Newer medications like olanzapine may significantly lower this risk, improving treatment safety.
Area of Science:
- Psychiatry
- Pharmacology
- Movement Disorders
Background:
- Antipsychotic medications can cause acute extrapyramidal symptoms and tardive dyskinesia.
- Understanding diagnostic subgroup vulnerability to drug-induced movement disorders is crucial for clinical practice and pathophysiology insights.
Purpose of the Study:
- To investigate if specific patient diagnostic subgroups have varying risks for developing tardive dyskinesia.
- To assess the potential of newer antipsychotic drugs to mitigate the risk of tardive dyskinesia.
Main Methods:
- Review of existing studies examining antipsychotic drug side effects.
- Analysis of data on diagnostic subgroups, focusing on affective disorders.
- Consideration of variables like age, sex, and treatment duration.
Main Results:
- Evidence suggests patients with affective disorders are at increased risk for tardive dyskinesia.
- Preliminary data indicate that novel antipsychotics, such as olanzapine, may reduce the incidence of tardive dyskinesia.
Conclusions:
- Affective disorder patients represent a vulnerable group for tardive dyskinesia.
- Newer antipsychotic agents show promise in improving the benefit-to-risk profile of long-term treatment, especially for these patients.